Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
aXichem AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was -44.87%.
The industry rank for aXichem AB's 3-Year RORE % or its related term are showing as below:
OSTO:AXIC A's 3-Year RORE % is ranked worse than 82.6% of 1517
companies
in the Chemicals industry
Industry Median: 6.39
vs OSTO:AXIC A: -44.87
aXichem AB (OSTO:AXIC A) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
aXichem AB 3-Year RORE % Related Terms
aXichem AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for aXichem AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:AXIC A vs LIN, SHW, ECL: 3-Year RORE % Comparison
For the Specialty Chemicals subindustry, aXichem AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aXichem AB 3-Year RORE % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, aXichem AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where aXichem AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
aXichem AB (OSTO:AXIC A) has a 3-Year RORE % of -44.87 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on aXichem AB and its competitors. According to the industry distribution chart, aXichem AB ranks #1253 out of 1517 companies in the Chemicals industry, placing it in the top 82.6%.
Is aXichem AB's 3-Year RORE % too high?
aXichem AB's current 3-Year RORE % is -44.87. Based on the distribution chart, aXichem AB ranks #1253 out of 1517 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, aXichem AB has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does aXichem AB's 3-Year RORE % compare to LIN and SHW?
According to the Chemicals industry distribution chart, aXichem AB ranks #1253 out of 1517 companies for 3-Year RORE %. This places aXichem AB in the lower half of its industry. The industry median 3-Year RORE % is 6.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Chemicals company?
The median 3-Year RORE % among Chemicals companies is 6.39, based on 1,517 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on aXichem AB and its competitors. For the Chemicals industry, the median 3-Year RORE % is 6.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aXichem AB's current 3-Year RORE % is -44.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aXichem AB stock overvalued right now?
Based on GuruFocus' analysis, aXichem AB (OSTO:AXIC A) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.59, compared to a current price of kr3.24 — trading 9.7% below its estimated fair value. The current 3-Year RORE % is -44.87. aXichem AB's overall GF Score™ is 66/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For aXichem AB (OSTO:AXIC A), the current 3-Year RORE % is -44.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aXichem AB (OSTO:AXIC A) Overvalued in 2026?
Based on GuruFocus' analysis, aXichem AB stock appears to be undervalued.
The current stock price of kr3.24 is trading 9.7% below its estimated GF Value™ of kr3.59.
GuruFocus considers aXichem AB to be Modestly Undervalued.
Key valuation signals for OSTO:AXIC A:
3-Year RORE %: -44.87
GF Value™: kr3.59 vs. price of kr3.24 (9.7% below fair value)
No single metric tells the full story. See the OSTO:AXIC A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aXichem AB develops, patents, markets and sells natural analogue industrial chemicals, which are synthetically produced substances with similar and comparable properties to natural substances. The Company's business concept is to develop, patent, market and sell natural analogue industrial chemicals. Its commercial focus is on the proprietary patented product phenylcapsaicin, the Company's first product, which is marketed under the registered trademarks aXiphen as an additive in animal feed and aXivite as an ingredient in food supplements and as a bioenhancer. The Company's product portfolio comprises Phenylcapsaicin, aXiphen, aXiphen bio, and aXivite. The Company's focus is on establishing aXiphen as an additive in poultry feed and pig feed.
66GF Score
Get the complete analysis for OSTO:AXIC A
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:AXIC A has been successfully added to your 
